Angiotensin II Receptor Blocker And Neprilysin Inhibitor Sacubitril/valsartan Attenuates Experimental Pulmonary Hypertension

被引：0
|
作者：
Clements, Richard T.
Vang, Alexander
Kue, Nouaying R.
Mancini, Thomas
Morrison, Alan R.
McCullough, Danielle J.
Mallem, Krishna
Choudhary, Gaurav
机构：
来源：
CIRCULATION | 2019年 / 140卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A17134
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy
    Yamamoto, T
    Sata, M
    Fukuda, D
    Takamoto, S
    BASIC RESEARCH IN CARDIOLOGY, 2005, 100 (01) : 84 - 91
  • [22] Entresto (Sacubitril/Valsartan): Angiotensin Receptor Neprilysin Inhibition for Treating Heart Failure
    Nicholas Phreaner
    Barry H. Greenberg
    Current Emergency and Hospital Medicine Reports, 2017, 5 (2) : 47 - 55
  • [23] The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) improves ejection fraction and longitudinal strain in mice treated with doxorubicin through NLRP3
    Quagliariello, V.
    Bonelli, A.
    Paccone, A.
    Buccolo, S.
    Iovine, M.
    Rea, D.
    Cerrone, F.
    Botti, G.
    Maurea, N.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2836 - 2836
  • [24] Neprilysin Inhibitor-Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E-Deficient Mice
    Zhang, Hui
    Liu, Gangqiong
    Zhou, Wenping
    Zhang, Wenjing
    Wang, Kai
    Zhang, Jinying
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [25] LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
    Martin P Lefkowitz
    BMC Pharmacology and Toxicology, 16 (Suppl 1)
  • [26] Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy
    Volpe M.
    Tocci G.
    Battistoni A.
    Rubattu S.
    High Blood Pressure & Cardiovascular Prevention, 2015, 22 (3) : 241 - 246
  • [27] Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure
    Fala, Loretta
    AMERICAN HEALTH AND DRUG BENEFITS, 2015, 8 (06):
  • [28] Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension
    Kia, Danial Sharifi
    Benza, Evan
    Bachman, Timothy N.
    Tushak, Claire
    Kim, Kang
    Simon, Marc A.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (13):
  • [29] LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease
    Suematsu, Yasunori
    Jing, Wanghui
    Nunes, Ane
    Kashyap, Moti L.
    Khazaeli, Mahyar
    Vaziri, Nosratola D.
    Moradi, Hamid
    JOURNAL OF CARDIAC FAILURE, 2018, 24 (04) : 266 - 275
  • [30] Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats
    Alqahtani, Faleh
    Mohany, Mohamed
    Alasmari, Abdullah F.
    Alanazi, Ahmed Z.
    Belali, Osamah M.
    Ahmed, Mohammed M.
    Al-Rejaie, Salim S.
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2020, 17 (18): : 3098 - 3106
12345